Chung, Hyun Cheol
Arkenau, Hendrik-Tobias
Lee, Jeeyun
Rha, Sun Young
Oh, Do-Youn
Wyrwicz, Lucjan
Kang, Yoon-Koo
Lee, Keun-Wook
Infante, Jeffrey R.
Lee, Sung Sook
Kemeny, Margaret
Keilholz, Ulrich
Melichar, Bohuslav
Mita, Alain
Plummer, Ruth
Smith, Denis
Gelb, Arnold B.
Xiong, Huiling
Hong, Janet
Chand, Vikram
Safran, Howard
Funding for this research was provided by:
Merck KGaA (NA)
Pfizer (NA)
Article History
Received: 24 October 2018
Accepted: 13 January 2019
First Online: 4 February 2019
Ethics approval and consent to participate
: The trial was conducted in accordance with the ethics principles of the Declaration of Helsinki and the International Council for Harmonisation Guidelines on Good Clinical Practice. The protocol was approved by the institutional review board or independent ethics committee of each center. All patients provided written informed consent before enrollment.
: Not applicable.
: HCC: consultant/advisory role: Bristol-Myers Squibb, Celltrion Healthcare, Eli Lilly, Merck & Co, Merck KGaA, Quintiles, Taiho Pharmaceutical; speakers bureau: Eli Lilly, Foundation Medicine, Merck KGaA; research grants: Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck & Co, Merck KGaA, Ono Pharmaceutical, Taiho Pharmaceutical.YKK: consulting or advisory role: Bristol-Myers Squibb, Eli Lilly, Ono Pharmaceutical, Roche; research funding: Bayer, Novartis, Roche, Sanofi.KWL: research funding: AstraZeneca/MedImmune, Daiichi Sankyo, Five Prime Therapeutics, Green Cross Corp, Macrogenics, Merck KGaA, Merck & Co, Ono Pharmaceutical, Taiho Pharmaceutical.UK: honoraria: AstraZeneca, Bristol-Myers Squibb, Glycotope GmbH, Merck KGaA, Merck & Co, Novartis, Pfizer, Roche/Genentech; consulting or advisory role: AstraZeneca, Bristol-Myers Squibb, Merck Serono, Merck & Co, Pfizer; speakers bureau: AstraZeneca, Bristol-Myers Squibb, Glycotope GmbH, Merck Serono, MSD Oncology, Novartis; research funding: Pfizer; travel, accommodations, expenses: AstraZeneca, Merck KGaA, Merck & Co.BM: honoraria: Bristol-Myers Squibb, Merck & Co, Merck KGaA, Novartis, Roche; consulting or advisory role: Bristol-Myers Squibb, Merck & Co, Merck KGaA, Novartis, Roche; travel, accommodations, expenses: Bristol-Myers Squibb, Novartis, Roche.AM: speakers bureau: Genentech.RP: honoraria: Bristol-Myers Squibb, Roche/Genentech; consulting or advisory role: AstraZeneca, BioMarin, Clovis Oncology, Karus Therapeutics, Mission Therapeutics, Merck & Co, Novartis, Roche/Genentech, Tesaro, Vertex; speakers bureau: Novartis; research funding: AstraZeneca/MedImmune, Clovis Oncology, Eisai, Etherapeutics, Ipsen, Vertex; patents, royalties, other intellectual property: named on patent for use of PARP inhibitor (rucaparib); travel, accommodations, expenses: Merck & Co, Roche/Genentech.ABG: employment: EMD Serono Inc. (a business of Merck KGaA, Darmstadt, Germany) when the study was performed; stock ownership: Halozyme Therapeutics.HX: employment: EMD Serono Inc. (a business of Merck KGaA, Darmstadt, Germany).JH: employment: EMD Serono Inc. (a business of Merck KGaA, Darmstadt, Germany).VC: employment: EMD Serono Inc. (a business of Merck KGaA, Darmstadt, Germany) when the study was performed; current employment at AstraZeneca; stock and other ownership interests: Bristol-Myers Squibb.HTA, JL, SYR, DYO, LW, JRI, SSL, MK, DS, and HS declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.